

Clinical Evidence for the Role of a Topical Anti-Inflammatory Agent in Comedonal Acne: Findings From a Randomized Study of Dapsone Gel 5% in Combination With Tazarotene Cream 0.1% in Patients With Acne Vulgaris

Emil Tanghetti MD,^a Sunil Dhawan MD,^b Lawrence Green MD,^c Mark Ling MD PhD,^d Jeanine Downie MD,^e Marguerite A. Germain MD,^f J. Scott Kasteler MD,^g Leon Kircik MD,^h Michael G. Oefelein MD,ⁱ Zoe Draelos MD^j

^aCenter for Dermatology and Laser Surgery, Sacramento, CA

^bCenter for Dermatology, Cosmetic and Laser Surgery, Fremont, CA

^cDepartment of Dermatology, George Washington University, Washington, DC

^dMedaPhase, Inc., Newnan, GA

^eImage Dermatology PC, Montclair, NJ

^fGermain Dermatology, Mt. Pleasant, SC

^gDivision of Dermatology, University of Louisville, Louisville, KY

^hPhysicians Skin Care PLLC, Louisville, KY

ⁱAllergan, Inc., Irvine, CA

^jDepartment of Dermatology, Duke University School of Medicine, Durham, NC

ABSTRACT

Background: Acne pathogenesis is multifactorial and includes inflammation. Combining drugs targeting multiple components of acne pathogenesis is standard practice.

Objective: To assess the safety and efficacy of dapsone gel 5%, an anti-inflammatory agent, in combination with tazarotene cream 0.1% for treatment of acne vulgaris.

Methods: Patients were randomized to receive combination therapy (dapsone gel 5% twice-daily plus tazarotene cream 0.1% daily) or monotherapy (tazarotene cream 0.1% daily). Efficacy and safety data were collected after 1, 2, 4, 8, and 12 weeks of treatment.

Results: Patients in both arms (n=86, dapsone + tazarotene; n=85, tazarotene) showed significant reductions from baseline in inflammatory, noninflammatory and total lesion counts ($P < .001$ for all). At 12 weeks, patients treated with dapsone plus tazarotene showed a greater reduction from baseline in noninflammatory (comedonal) and total lesion counts than tazarotene-treated patients (noninflammatory, 59.7 percent vs. 46.5 percent, $P = .01$; total, 63.3% vs. 53.6%, $P = .02$). The percentage of patients achieving treatment success (an investigator subjective score of 0 [none] or 1 [minimal]) was greater in dapsone plus tazarotene-treated patients (42.2%) than in tazarotene-treated patients (21.8%; $P = .01$). Both treatments were well tolerated.

Conclusion: Combination therapy with dapsone gel 5% plus tazarotene cream 0.1% was more effective than tazarotene monotherapy for treatment of comedonal acne. The results suggest that anti-inflammatory agents such as dapsone can effectively treat early stages of acne (both comedonal and noncomedonal) when used in combination with a retinoid.

J Drugs Dermatol. 2011;10(7):783-792.

INTRODUCTION

Acne, a common condition that can persist for years beyond adolescence,¹ may result in scarring and post-inflammatory hyperpigmentation (PIH).² The pathogenesis of acne is multifactorial and still not fully understood. Current dogma for acne pathogenesis suggests that follicular hyperkeratinization, abnormal epithelial desquamation and sebaceous gland hyperplasia lead to micro-

comedo formation. Continuous accumulation of sebum and deposition of keratinous material lead to development of lesions (open and closed comedones) traditionally classified as noninflammatory or, with proliferation of *Propionibacterium acnes* and induction of immunomodulatory events, inflammatory lesions.^{3,4}

The current model for acne pathogenesis, which focuses on the role of *P. acnes* in inflammatory lesion development, has been brought into question based on accumulating evidence suggesting that inflammation is present throughout the development of acne lesions, even when not clinically apparent, from microcomedones to residual erythematous lesions and PIH.^{5,6} The pro-inflammatory cytokines, interleukin (IL)-1 α , IL-1 β , and tumor necrosis factor (TNF)- α , have been found in open comedones.⁷ Moreover, follicular IL-1 α and IL-1RTII expression in uninvolved skin of patients with acne was found to be three-fold and thirty-fold higher, respectively, than corresponding levels in normal skin, despite a proliferative and differentiated state of the follicles in uninvolved skin of patients with acne that was histologically comparable to that of follicles in normal skin.⁵ Thus, IL-1 α from uninvolved follicles in skin of patients with acne has been proposed as an initiating factor for a nonspecific inflammatory response in the skin around the pilosebaceous follicle that occurs prior to, and not as a result of, hyperproliferative or aberrant differentiation events.⁵ Early acne inflammation also appears to involve neutrophils, among other inflammatory cells and biochemical mediators of inflammation. Once present at the acne site, neutrophils can recruit additional neutrophils and generate reactive oxygen species that further damage tissue.⁸⁻¹¹ This novel concept raises the possibility that early subclinical inflammation may play a pathogenic role in the formation of not only visible inflammatory lesions, but also in the development of microcomedonal lesions heretofore considered "noninflammatory." This pathogenic model of acne in turn suggests that anti-inflammatory therapies may be suitable for treating both early comedonal as well as later inflammatory lesions in acne.

©Dapsone gel 5% (ACZONE®; Allergan, Inc, Irvine, CA) is a topical anti-acne medication with an anti-inflammatory mechanism of action. In two randomized studies involving more than 3,000 patients, dapsone gel 5% was found to be safe and effective for the treatment of acne vulgaris (both comedonal and non-comedonal acne).¹² With its anti-inflammatory mechanism of action and favorable tolerability profile, dapsone gel 5% seems well suited for use in combination with a retinoid for acne treatment. The purpose of this study was to assess the safety and efficacy of dapsone gel 5% co-administered with tazarotene cream 0.1% in patients with moderate-to-severe inflammatory and comedonal facial acne.

METHODS

Patients

Male or female patients at least 12 years of age with stable, non-rapidly progressing facial acne vulgaris were eligible for inclusion in the study. Facial acne vulgaris was characterized by the presence of 50 to 100 inflammatory lesions (papules, pustules), 25 to 100 facial noninflammatory lesions (open/closed comedones), and no more than three facial nodules and/or cysts of diameter ≥ 1 cm.

Patients with a skin disease or disorder that might interfere with the diagnosis or evaluation of acne vulgaris or who failed to comply with the protocol-specified wash-out periods for prohibited medications were excluded. Additional exclusion criteria were a history of clinically significant anemia or hemolysis and evidence of recent alcohol or drug abuse. Females of childbearing potential were required to use reliable methods of birth control. Patients with a history of poor cooperation or noncompliance with medical treatment or who failed to comply with specified procedures were also excluded.

Study Design

This was a 12-week, multicenter, single-blinded, randomized, parallel-group study. Patients were assigned 1:1 by computer randomization to receive dapsone gel 5% in the morning and evening plus tazarotene cream 0.1% in the evening, or tazarotene cream 0.1% in the evening alone for 12 weeks. Patients were provided with coded treatment kits and the treatment was self-administered. In the combination treatment arm, the evening application of dapsone gel 5% was applied before tazarotene cream 0.1%. Use of facial moisturizer and cleanser was restricted to those products supplied within the study.

Patient compliance with treatment was assessed verbally at each visit. Patients were asked by study personnel whether any applications of study medication were missed since the previous visit and their responses quantified.

Patients attended study visits at baseline and at weeks 1, 2, 4, 8, and 12 during treatment. The primary efficacy variable was the inflammatory lesion count at all time points, defined as the number of papules/pustules on the face only, from the hairline edge to the mandibular line.

Secondary efficacy variables were assessed at all time points and included noninflammatory and total (inflammatory + noninflammatory) lesion counts. In addition, four other investigator-completed assessments were conducted at baseline and at each clinic visit: investigator global assessment (IGA; also referred to as the global assessment of acne severity [GAAS]), overall disease severity, disease signs and symptoms, and PIH. The IGA was conducted using an ordinal scale ranging from zero to 4, where zero indicates no evidence of acne vulgaris, and 4 indicates a significant degree of inflammatory disease, a predominance of papules and pustules, and the possible presence of nodulo-cystic lesions and comedones. Overall disease severity (including size of lesions, overall degree of inflammation, general erythema and skin condition) was quantified using an ordinal rating scale ranging from zero to 6, where zero indicates no disease present (clear, no inflammatory lesions) and 6 indicates severe disease (numerous comedones, papules, and pustules with larger inflamed lesions extending over much of the face, and erythema may be pronounced). Disease signs and

TABLE 1.

Baseline Demographics and Disease Characteristics				
	Tazarotene (n = 85)	Dapsone + Tazarotene (n = 86)	All Patients (N = 171)	P
Gender, n (%)				
Male	49 (57.6)	38 (44.2)	87 (50.9)	.0783
Female	36 (42.4)	48 (55.8)	84 (49.1)	
Age, y				
Mean \pm SD	19.4 \pm 6.5	20.2 \pm 6.9	19.8 \pm 6.7	.3678
Median (range)	16.7 (12.1-42.9)	17.8 (12.2-45.7)	17.2 (12.1-45.7)	
Race, n (%)				
White	48 (56.5)	52 (60.5)	100 (58.5)	.0649
Black	22 (25.9)	9 (10.5)	31 (18.1)	
Hispanic	3 (3.5)	8 (9.3)	11 (6.4)	
Asian	4 (4.7)	5 (5.8)	9 (5.3)	
Other	8 (9.4)	12 (14.0)	20 (11.7)	
Inflammatory lesions, mean \pm SD	40.8 \pm 12.9	38.9 \pm 11.7	39.9 \pm 12.3	.1564
Noninflammatory lesions, mean \pm SD	46.5 \pm 16.9	46.4 \pm 17.4	46.5 \pm 17.1	.7316
Total lesions, mean \pm SD	87.3 \pm 24.2	85.4 \pm 22.3	86.3 \pm 23.2	.5376
IGA score, mean \pm SD	3.04 \pm 0.36	2.93 \pm 0.37	2.98 \pm 0.37	.0619

symptoms relating to the current severity of erythema (disease related and/or related to retinoid use), dryness, peeling and oiliness were rated using an ordinal rating scale ranging from zero (no erythema or dryness, smooth skin, normal oiliness) to 4 (beet red erythema; easily noted dryness with accentuation of skin markings, skin desquamation, and/or fissure formation; extensive peeling and prominent oiliness). In addition, the degree of pruritus and burning was quantified using a numerical scale ranging from zero (normal, no discomfort) to 5 (definite, continuous discomfort interfering with normal daily activities). Distribution and severity of PIH was determined using one scoring system to assess the percentage of the face affected, ranging from zero (none) to 6 (>50%); and a second scale was used to quantify the severity of PIH ranging from zero (absent) to 5 (severe).

The safety of the study medication was assessed throughout the study by recording adverse events at each study visit.

Assessments were performed by investigators blind to the treatment assignment.

Statistical Analyses

It was calculated that 80 patients per treatment group (total sample size 160 patients) were required to yield 80 percent power to detect a difference of 15 percent in the primary outcome parameter, the percentage reduction of inflammatory lesions after 12 weeks of treatment, assuming a standard deviation of 31 percent in both groups and an approximate drop-out rate of 15 percent.


Statistical analyses were conducted on the intent-to-treat population, which included all enrolled subjects. All statistical tests were two-sided and interpreted at a 5% significance level. Descriptive statistics were calculated for all continuous variables, and frequencies for all categorical variables. Where the necessary assumptions for parametric tests were satisfied, comparisons were performed using analysis of covariance with the baseline value as the covariate. The Wilcoxon rank sum test was used if the necessary assumptions for parametric tests were not satisfied. Safety analyses were performed according to the incidence and severity of local tolerability, signs and symptoms, and adverse and/or unexpected events.

Missing data were imputed by the method of last observation carried forward (LOCF).

RESULTS

Patient Disposition and Demographics

One hundred seventy-one patients were enrolled in the study (Table 1). Treatment groups were generally similar with regard to baseline demographic characteristics; however, the proportion of female patients was higher in the combination arm compared with the monotherapy arm. Baseline lesion counts were similar between treatment arms. Mean baseline inflammatory and noninflammatory lesion counts were 40 and 47 in the overall study population, indicating that study patients had at least moderate acne. The median IGA score was 3.0, also consistent with a moderate acne severity designation.




FIGURE 1. Schematic profile of patient disposition.

Of the 171 enrolled patients, 160 completed treatment and 11 withdrew early (Figure 1). Three patients receiving dapsone plus tazarotene and eight patients receiving tazarotene monotherapy withdrew prior to completion of the study. None of the withdrawals was due to adverse tolerability.

Inflammatory Lesion Count

There was a significant reduction in inflammatory lesion count compared with baseline in both treatment arms (Figure 2), and at week 12 the mean change from baseline count was -25.77 ± 11.23 lesions in the dapsone plus tazarotene group and -24.82 ± 14.06 lesions in the tazarotene monotherapy group ($P < .0001$ for both treatment groups vs. baseline). However, the magnitude of inflammatory lesion count reduction was not significantly different between the two treatment groups at any time point. At week 12, the mean percentage change from baseline inflammatory lesion count was 66.6 percent for the dapsone plus tazarotene combination therapy group versus 60.9 percent for the tazarotene monotherapy group ($P = 0.17$).

Despite the similarity in magnitude of response at week 12, the onset of effect with combination therapy occurred earlier than with tazarotene monotherapy. At week 2, significantly more patients receiving combination therapy than patients receiving monotherapy achieved a 50 percent reduction in inflammatory

FIGURE 2. Mean number of a) inflammatory, b) noninflammatory, and total c) lesions at baseline and at 12 weeks with tazarotene monotherapy or dapsone plus tazarotene combination therapy. Error bars represent standard deviations.


* $P < .0001$ compared with baseline value. Combination treatment resulted in a significantly greater reduction in noninflammatory ($P = .0376$) and total ($P = .0250$) lesion numbers; however, inflammatory lesions were reduced to a similar extent in both treatment arms ($P > .05$).

TABLE 2.

Adverse Events Possibly Related to Study Treatment		
Adverse Event	Tazarotene (n = 84) No. (%) of Patients	Dapsone + Tazarotene (n = 86) No. (%) of Patients
Dryness	2 (2.4%)	2 (2.3%)
Erythema	4 (4.8%)	2 (2.3%)
Peeling	1 (1.2%)	0 (0.0%)
Pruritus corners of the mouth	1 (1.2%)	0 (0.0%)
Sunburn on face, arms, and shoulders	1 (1.2%)	0 (0.0%)

Note: Patients reporting a particular adverse event more than once are counted only once for that adverse event.

FIGURE 3. Percentage of patients achieving treatment success at week 12 as measured by IGA score of 0 (none) or 1 (minimal).



lesion count (27.4% vs. 12.7%, respectively, $P=0.02$). Similarly, at weeks 4 and 8, significantly more patients receiving combination therapy than those receiving monotherapy achieved a 75 percent reduction in inflammatory lesion count (week 4, 13.4% vs. 3.8%, $P=.03$; week 8, 22.8% vs. 10.1%, $P=.03$).

Secondary End Points

Noninflammatory and total lesion counts

After 12 weeks of therapy, there was a significant reduction in noninflammatory lesion count compared with baseline in both treatment arms (Figure 2). Notably, the magnitude of reduction was significantly greater in the combination therapy arm than in the monotherapy arm (59.7% vs. 46.5%, $P=0.01$). Similarly, the decline in total lesion count at week 12 was also significantly greater in the dapsone plus tazarotene combination therapy group compared with the tazarotene monotherapy group (63.3% vs. 53.6%, $P=.02$). Furthermore, the more rapid

onset of effect with the combination therapy than with monotherapy was evident as early as week 1 when evaluating total lesion count. At week 1, significantly more patients receiving combination therapy than those receiving monotherapy achieved a 50 percent decline in total lesion count (10.6% vs. 1.2%, $P=.02$), and at weeks 4 and 8, the proportions of patients achieving a 75 percent decline in total lesion count was also significantly greater in the combination arm than in the monotherapy arm (week 4, 9.8% vs. 1.3%, $P=.03$; week 8, 20.3% vs. 3.8%, $P=.002$).

Investigator global assessment score

Mean baseline IGA scores were 2.93 ± 0.37 for patients randomized to dapsone plus tazarotene and 3.04 ± 0.36 for patients receiving tazarotene monotherapy, reflecting moderate acne severity, on average, in both treatment arms. Both treatment groups demonstrated improvement from baseline acne severity at all time points based on the IGA end point. At week 12, the percentage of patients achieving treatment success (defined as achieving a score of 0 [none] or 1 [minimal]) was significantly greater in the dapsone plus tazarotene-treated patients than in the patients treated with tazarotene monotherapy ($P=.006$; Figure 3).

Overall disease severity score

Mean baseline overall disease severity scores were similar between treatment groups (combination dapsone plus tazarotene, 4.03, vs. tazarotene monotherapy, 4.08; $P=.65$), and at week 12, there were significant reductions in scores, indicating improvement in disease severity ($P < 0.0001$) in both treatment arms. However, at week 12, patients treated with combination therapy demonstrated a significantly lower mean disease severity score than did patients treated with monotherapy (2.11 vs. 2.44, $P=.03$).

Disease signs and symptoms

Baseline scores for each of erythema, dryness, peeling, and oiliness were similar between treatment groups. After 12 weeks of therapy, there were significant improvements in the scores for erythema ($P \leq 0.020$) and oiliness ($P < 0.001$) compared with baseline in both treatment arms, but no significant change in dryness or peeling in either treatment arm (Figures 4 and 5). There was no difference between treatment groups in any of the disease signs/symptoms assessed.

Post-inflammatory hyperpigmentation

At baseline, the severity and distribution of PIH were similar between treatment groups (mean severity: 0.84 ± 1.20 and 0.84 ± 1.16 ; mean distribution: 0.90 ± 1.41 and 0.93 ± 1.40 for combination vs. monotherapy, respectively). At 12 weeks, the mean change in severity from baseline was -0.27 ± 0.84 with dapsone plus tazarotene combination treatment and -0.22 ± 0.71 with tazarotene monotherapy ($P=.01$ and $P=.01$ versus baseline for combination therapy and monotherapy, respectively; $P=.48$ be-

FIGURE 5. Disease signs and symptoms over the course of treatment: mean scores over time. Severity of erythema, dryness, peeling, and oiliness were rated according to the following scale: 0 = absent; 1 = trace; 2=mild; 3=moderate; 4=severe.








FIGURE 5. Representative patient photos. Patients at baseline (a, c) and after treatment with dapson + tazarotene for 12 weeks (b, d).



tween groups). The mean change in PIH distribution at 12 weeks was -0.31 ± 0.87 with combination treatment and -0.27 ± 0.91 with monotherapy ($P = .001$ and $P = .01$ vs baseline for combination therapy and monotherapy groups, respectively; $P = .39$ between groups).

Safety

Adverse events related to treatment were limited to local application-site reactions for both treatment groups, and dryness and erythema were the most frequently reported adverse events. The majority of adverse events were mild or moderate and resolved without sequelae. In total, four adverse events reported for patients treated with combination therapy were considered related to study treatment (erythema, $n=2$; dryness, $n=2$); all were mild or moderate and in each case study medication was temporarily discontinued and then reintroduced with no further adverse events (Table 2). Nine adverse events reported in 6 monotherapy-treated patients were considered related or probably related to therapy (erythema, $n=4$; dryness, $n=2$; and sunburn, pruritus, peeling, $n=1$ each). These events were mild or moderate, except for the occurrence of dryness ($n=1$) and peeling ($n=1$) in a single patient, which were considered severe. In all cases, either no action was necessary or study medication was temporarily discontinued and then reintroduced with no further adverse events. There were no serious adverse events reported and no patients were withdrawn from treatment due to an adverse event.

DISCUSSION

Most anti-acne medications do not act against all of the inflammatory and other pathophysiologic features of acne. Thus, the standard of care in acne treatment in the U.S. is treatment with combinations of drugs that target multiple components of acne pathogenesis. ACZONE is a topical formulation of 5% dapsones approved in the U.S. for the treatment of acne vulgaris. It has an anti-inflammatory profile that includes inhibition of neutrophil recruitment and adhesion,^{8-10,13} and inhibition of the production and release of tissue-damaging agents such as matrix-degrading enzymes and superoxides.^{11,14} Dapsone also blocks macrophage infiltration and activation, as well as the production of, and signaling by, inflammatory mediators such as prostaglandins, leukotrienes and cytokines.^{8-10,15-17} There are no published reports of dapsones having any activity against *P. acnes*. Despite its anti-inflammatory profile, dapsones 5% gel has demonstrated efficacy against both noninflammatory and inflammatory components of acne, as demonstrated in the two pivotal trials.¹²

The efficacy of dapsones gel 5% monotherapy has been demonstrated in randomized clinical trials, and its safety profile has been confirmed for up to 12 months in long-term follow-up studies.^{12,18,19} Additional studies have shown that dapsones gel

5% is also an effective treatment when used in combination with other acne treatments with apparently nonoverlapping, complimentary mechanisms of action, such as adapalene gel 0.1%, a retinoid, and benzoyl peroxide (BPO) gel 4%, an antibacterial agent.²⁰ The findings of the present study extend the observations from previous studies by evaluating the efficacy of the retinoid, tazarotene, in combination with dapsones gel 5%. The patients enrolled in this study had, on average, moderate acne. The results from our study show that combination therapy with dapsones gel 5% and tazarotene cream 0.1% is a safe and effective treatment for patients with at least moderate acne vulgaris.

Both tazarotene cream 0.1% monotherapy and the combination of tazarotene cream 0.1% with dapsones gel 5% were well tolerated in this study. Adverse events related to treatment were limited to local application-site reactions for both treatment groups. Importantly, addition of dapsones to tazarotene did not appear to be associated with additional tolerability concerns.

Efficacy was demonstrated in this study by evaluation of investigator ratings (IGA and disease severity scores), signs and symptoms of acne, PIH, and lesion counts. Investigator ratings indicated significantly greater improvements in both the IGA and disease severity scores with tazarotene plus dapsones combination therapy than with tazarotene monotherapy. In addition, the IGA revealed a greater proportion of patients achieving a response of "clear" or "almost clear" with combination therapy versus monotherapy ($P < 0.006$). The IGA metric is important, and the IGA and other similar subjective global assessments have been acknowledged as being more clinically relevant than lesion counts alone. Indeed, the U.S. Food and Drug Administration (FDA) has recommended the use of both lesion counts and subjective global assessments as co-primary end points in acne clinical trials.²¹ The recommendation stems from the recognition that acne lesion counts can be imprecise and impractical in the clinical setting.²² Moreover, unlike lesion counts, subjective global assessments consider other signs and symptoms, such as erythema and oiliness among others, in the determination of acne severity, and thus more accurately reflect the pleomorphic nature of this disease.²² When used to evaluate treatment effectiveness, these subjective assessments measure subtle treatment effects that may be overlooked with lesion count reductions alone.

Both tazarotene monotherapy and tazarotene in combination with dapsones favorably impacted signs and symptoms of acne and PIH. The two treatment regimens decreased oiliness and erythema to a similar degree relative to baseline assessments. The reduction in severity and distribution of PIH was also comparable between treatment groups. This is particularly important for patients with skin of color, for whom PIH is a concern when treating their acne.²³

In this study, dapsonе gel 5% plus tazarotene cream 0.1% combination treatment and tazarotene cream 0.1% monotherapy were associated with a reduction in the numbers of both inflammatory and noninflammatory lesions. It is acknowledged that this study failed to meet its primary end point, since at 12 weeks, the between-group difference in reduction of inflammatory lesion counts did not reach statistical significance. However, we found an intriguing between-group difference in the reduction of noninflammatory (and total) lesions; this difference was statistically significant and favored combination dapsonе plus tazarotene treatment, indicating that dapsonе is active against noninflammatory lesions.

Consistent with this observation, a combined analysis of two previous studies demonstrated the effect of dapsonе gel 5% monotherapy on comedonal acne.¹² Dapsonе 5% gel reduced comedonal acne lesion counts from baseline by 32 percent at 12 weeks, compared with a 24 percent reduction seen with placebo treatment. The eight percent treatment effect was significant and suggested a role for dapsonе 5% gel in the treatment of comedonal acne. Thus, despite its anti-inflammatory profile, dapsonе 5% gel is effective against comedonal acne, a lesion type traditionally considered to be noninflammatory.

Other clinical studies have reported that the antibiotic and anti-inflammatory agent clindamycin, when combined with topical BPO, significantly reduces comedonal lesions.²⁴⁻²⁶ A 12-week clinical study evaluating the combination of tazarotene cream 0.1% plus clindamycin/BPO in comparison with tazarotene cream 0.1% monotherapy also demonstrated that patients treated with the combination therapy (retinoid plus antibacterial/anti-inflammatory agent) achieved a significantly greater reduction in comedonal lesion counts after 12 weeks than with the retinoid alone.²⁷ These findings, together with our observations of dapsonе effects in this and previous studies, suggest that topical anti-inflammatory therapy may impact the initiation and propagation of inflammatory events, which in turn may interfere with the development of comedonal acne. However, BPO (in the clindamycin/BPO combination) has direct comedolytic properties as well as anti-inflammatory characteristics, and these may have contributed to the effects observed in studies of this agent.

The involvement of inflammation as part of immune system activation in the development of early-stage acne is supported by the following findings: inflammatory cells are found within the peripheral dermis of the microcomedo⁶; the pro-inflammatory cytokines, IL-1 α , IL-1 β , and TNF- α , are present in open comedones⁷; and inflammatory lesions can arise from clinically unaffected skin and sebaceous follicles.²⁸ Innate immune system components also may contribute to comedonal acne, as suggested by the constitutive expression of pro-inflammatory cytokines in the sebaceous glands^{29,30} and of antimicrobial

peptides in the pilosebaceous unit. These antimicrobial peptides may protect the follicle from microbial invasion; indeed, increased levels of antimicrobial peptides are often found in inflamed or infected skin of patients with acne vulgaris, with higher expression levels in lesional skin (comedones and papules) than in nonlesional areas.³¹ Furthermore, a recent report suggests that antimicrobial activity of sebocytes is mediated by beta-defensin-2 expression.³² Another report describes the expression of Toll-like receptor (TLR)-2, the activation of which elicits immune responses, on the cell surface of macrophages surrounding pilosebaceous follicles.³³ A separate study has demonstrated that all-trans retinoic acid downregulates TLR-2 expression and inhibits its activation in primary human monocytes.³⁴ Considering these data collectively, it is tempting to speculate that the presence of inflammation within comedones explains the findings of our study; more specifically, why dapsonе as an anti-inflammatory agent enhanced the efficacy of tazarotene in reducing comedonal lesions. If inflammation does contribute to the development of comedonal acne, then anti-inflammatory agents such as dapsonе may directly reduce comedonal lesions as well as enhance the effectiveness of retinoids in the treatment of comedonal acne by interfering with various components of the inflammatory process. However, alternative hypotheses to explain our findings are also possible, including that dapsonе may have as-yet unidentified direct effects on keratinization, corneocyte adhesion, or even sebaceous gland output that might result in comedolysis unrelated to anti-inflammatory mechanisms. Anti-acne therapies characterized by multiple modes of action are well known, and dapsonе may be another such anti-acne medication. The exact mechanism(s) by which dapsonе exerts its comedonal reduction effect requires further study.

If dapsonе does indeed act via an anti-inflammatory mechanism, it raises the question of why no additional effect of dapsonе on inflammatory lesions was noted in this study when it was used in combination with tazarotene cream. The significant clinical benefit of dapsonе 5% gel monotherapy on inflammatory lesions has been described previously.¹² A possible explanation for these apparently equivocal findings is that the effect of dapsonе on inflammatory lesions requires more time to manifest itself, and inflammatory lesions are more refractory to its effects, such that the effects of dapsonе on inflammatory lesions would not be observed in this small, possibly underpowered study.

Current consensus guidelines recommend the use of only topical retinoids to treat comedonal acne. Several topical agents with differing mechanisms, including dapsonе, multiple retinoids, BPO, and antibiotics are currently available for treatment of patients with acne. Dapsonе 5% gel has been shown to reduce comedonal lesions when used as monotherapy.¹² Two separate combination treatment studies, our current study and that conducted by Tanghetti and colleagues,²⁷ have now also

shown that combination of an anti-inflammatory agent, or BPO and topical antibiotic, with a retinoid may enhance therapeutic efficacy of the retinoid in comedonal acne. The efficacy of anti-inflammatory anti-acne agents in combination with a topical retinoid for reduction of comedonal acne challenges the perception that retinoids alone are indicated for the treatment of this condition. It also suggests that early inflammatory events are important in the development of microcomedones or comedones. The combination of topical tazarotene cream 0.1% with dapsone 5% gel appears to be useful in patients with comedonal acne, and offers a BPO- and oral antibiotic-free treatment alternative for patients with moderate to severe inflammatory acne.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the patients who participated in this study and thank Bianca Ruzicka, PhD, of ApotheCom, for her editorial assistance in developing this manuscript.

DISCLOSURES

Dr. Tanghetti is an investigator and speaker for Allergan and Steifel Laboratories, and is a consultant and speaker for Galderma Laboratories.

Dr. Dhawan is an investigator and speaker for Allergan, Galderma Laboratories, and Steifel Laboratories, and is an investigator for Graceway Pharmaceuticals.

Dr. Green is an advisor, consultant, and investigator for Allergan, a consultant and investigator for Steifel Laboratories, an investigator for Obagi Medical, an advisor for Galderma Laboratories, and a speaker for Warner Chilcott.

Dr. Ling is an investigator for Allergan, Cipher Pharmaceuticals, Spear Pharmaceuticals, and Steifel Laboratories.

Dr. Downie is an investigator, advisor, consultant and speaker for Allergan.

Dr. Germain is an advisor and investigator for Allergan, an advisor for Medicis Pharmaceutical, a consultant and speaker for Amgen and Doak Dermatologics, an advisor and consultant for Intendis, a speaker for Galderma Laboratories and Promius Pharma, and an advisor, consultant and speaker for Graceway Pharmaceuticals.

Dr. Kasteler is an investigator and speaker for Allergan, an investigator for Dow Pharmaceutical Sciences, Galderma Laboratories, and Steifel Laboratories, and a speaker for Amgen.

Dr. Kircik is an investigator, advisor, consultant, and/or speaker for 3M, Abbott Laboratories, Acambis, Allergan, Amgen, Assos

Pharma, Astellas, Asubio, Berlex Laboratories, Biogen-Idec, Biolife, Breckinridge Pharma, Centocor, Inc, Colbar, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermik Laboratories, Dow Pharmaceutical Sciences, Dusa, Embil Pharmaceuticals, EOS, Ferndale Laboratories, Galderma Laboratories, Genentech, GlaxoSmithKline, Health Point, Innovail, Intendis, Johnson & Johnson, Laboratory Skin Care, Leo, Medical International Technologies, Medicis Pharmaceutical Corp, Merz, Nano Bio, Novartis AG, Nucryst Pharmaceuticals, Obagi, OLT, Onset, OrthoNeutrogena, Pfizer, PharmaDerm, Promius, Quatrix, Serono, SkinMedica, Stiefel Laboratories, TolerRx, Triax, UCB, Valeant Pharmaceuticals, Warner-Chilcott, and ZAGE.

Dr. Oefelein is an employee of Allergan. Dr. Draelos is an investigator for Allergan, Galderma Laboratories, Medicis Pharmaceutical and Steifel Laboratories.

Third-party medical writing assistance with support from Allergan, Inc was used in the preparation of this manuscript. The authors, however, were fully responsible for content and editorial decisions.

This study was supported by Allergan, Inc.

REFERENCES

1. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. *J Am Acad Dermatol*. 2008;58:56-59.
2. Halder RM, Nootheti PK. Ethnic skin disorders overview. *J Am Acad Dermatol*. 2003;48:S143-S148.
3. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: Recent data, new understanding of the treatments. *Eur J Dermatol*. 2004;14:4-12.
4. Harper JC, Thiboutot DM. Pathogenesis of acne: Recent research advances. *Adv Dermatol*. 2003;19:1-10.
5. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. *J Invest Dermatol*. 2003;121:20-27.
6. Strauss JS, Pochi PE, Downing DT. Acne: Perspectives. *J Invest Dermatol*. 1974;62:321-325.
7. Ingham E, Eady EA, Goodwin CE, et al. Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. *J Invest Dermatol*. 1992;98:895-901.
8. Booth SA, Moody CE, Dahl MV, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. *J Invest Dermatol*. 1992;98:135-140.
9. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. *J Leukoc Biol*. 1997;62:827-836.
10. Maloff BL, Fox D, Bruin E, Di Meo TM. Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels. *Eur J Pharmacol*. 1988;158:85-89.
11. Suda T, Suzuki Y, Matsui T, et al. Dapsone suppresses human neu-

- trophil superoxide production and elastase release in a calcium-dependent manner. *Br J Dermatol.* 2005;152:887-895.
12. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapson gel, 5% for the treatment of acne vulgaris. *J Am Acad Dermatol.* 2007;56:439-410.
 13. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. *J Invest Dermatol.* 1978;70:51-55.
 14. Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapson. *Biochem Pharmacol.* 1992;44:553-563.
 15. Bonney RJ, Wightman PD, Dahlgren ME, et al. Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. *Biochem Pharmacol.* 1983;32:361-366.
 16. Wozel G, Lehmann B. Dapson inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. *Skin Pharmacol.* 1995;8:196-202.
 17. Abe M, Shimizu A, Yokoyama Y, et al. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus. *Clin Exp Dermatol.* 2008;33:759-763.
 18. Raimer S, Maloney JM, Bourcier M, et al. Efficacy and safety of dapson gel 5% for the treatment of acne vulgaris in adolescents. *Cutis.* 2008;81:171-178.
 19. Lucky AW, Maloney JM, Roberts J, et al. Dapson gel 5% for the treatment of acne vulgaris: Safety and efficacy of long-term (1 year) treatment. *J Drugs Dermatol.* 2007;6:981-987.
 20. Fleischer AB, Shalita A, Eichenfield LF, et al. Dapson gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or moisturizer for the treatment of acne vulgaris: A 12-week, randomized, double-blind study. *J Drugs Dermatol.* 2010;9:33-40.
 21. Center for Drug Evaluation and Research. *Guidance for Industry; Acne Vulgaris: Developing Drugs for Treatment.* Rockville, MD: Center for Drug Evaluation and Research, US Food and Drug Administration. 2005.
 22. Tan JKL. Current measures for the evaluation of acne severity. *Expert Rev Dermatol.* 2008;3:595-603.
 23. Shah SK, Alexis AF. Acne in skin of color: Practical approaches to treatment. *J Dermatolog Treat.* 2010;21:206-211.
 24. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. *Clin Ther.* 2002;24:1117-1133.
 25. Dhawan SS. Comparison of 2 clindamycin 1%-benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris. *Cutis.* 2009;83:265-272.
 26. Langner A, Sheehan-Dare R, Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. *J Eur Acad Dermatol Venereol.* 2007;21:311-319.
 27. Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: A multicenter, double-blind, randomized parallel-group trial. *J Drugs Dermatol.* 2006;5:256-261.
 28. Do TT, Zarkhin S, Orringer JS, et al. Computer-assisted alignment and tracking of acne lesions indicate that most inflammatory lesions arise from comedones and de novo. *J Am Acad Dermatol.* 2008;58:603-608.
 29. Anttila HS, Reitamo S, Saurat JH. Interleukin 1 immunoreactivity in sebaceous glands. *Br J Dermatol.* 1992;127:585-588.
 30. Boehm KD, Yun JK, Strohl KP, Elmets CA. Messenger RNAs for the multifunctional cytokines interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor-alpha are present in adnexal tissues and in dermis of normal human skin. *Exp Dermatol.* 1995;4:335-341.
 31. Chronnell CM, Ghali LR, Ali RS, et al. Human beta defensin-1 and -2 expression in human pilosebaceous units: Upregulation in acne vulgaris lesions. *J Invest Dermatol.* 2001;117:1120-1125.
 32. Nakatsuji T, Kao MC, Zhang L, et al. Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. *J Invest Dermatol.* 2010;130:985-994.
 33. Kim J. Review of the innate immune response in acne vulgaris: Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. *Dermatology.* 2005;211:193-198.
 34. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: All-trans retinoic acid down-regulates TLR2 expression and function. *J Immunol.* 2005;174:2467-2470.

ADDRESS FOR CORRESPONDENCE

Emil Tanghetti, MD

Center for Dermatology and Laser Surgery

5601 J Street

Sacramento, CA, 95819

Phone:.....(916) 454-5922

Fax:.....(916) 454-2156

E-mail:.....et@dermatologyandlaserurgery.com